Pharmaniaga to ride on high demand for its products

时间:2周前   阅读:8

澳5开户www.a55555.net)是澳洲幸运5彩票官方网站,开放澳洲幸运5彩票会员开户、澳洲幸运5彩票代理开户、澳洲幸运5彩票线上投注、澳洲幸运5实时开奖等服务的平台。

MIDF Research said the group has increased its profitability in the last few months as demand for pharmaceutical products continued to rise well into the second half of the year.

KUALA LUMPUR: Pharmaniaga Bhd is expected to post positive earnings in financial years 2022 (FY22) and FY23 as demand for pharmaceutical products continues to increase.

In a note, MIDF Research said the group has increased its profitability in the last few months as demand for pharmaceutical products continued to rise well into the second half of the year.

“Despite having no problems with raw materials, Pharmaniaga has stated that the high demand has caused manufacturing to go beyond 100% capacity, and paracetamol production had increased to more than twice the normal capacity.

“Liquid drugs are also facing a demand and supply imbalance, as such, Pharmaniaga’s Indonesian plants have been requested to deliver the syrups,” the research house pointed out.

,

皇冠代理网址www.hg9988.vip)是一个开放皇冠代理网址即时比分、皇冠手机网址代理最新登录线路、皇冠手机网址会员最新登录线路、皇冠网址代理APP下载、皇冠网址会员APP下载、皇冠网址线路APP下载、皇冠网址电脑版下载、皇冠网址手机版下载的皇冠新现金网平台。

,

MIDF Research also added that Pharmaniaga’s logistics segment will be renewing its concession agreement with the government in the fourth quarter of 2022, assuring a steady order of drugs for public hospitals in the near term.

Additionally, the group’s efforts to push its brands to become household names could reset the public sentiment that only certain brands of drugs would give out the same effect, hence boosting its future income.

“We are also optimistic on its vending machine venture which is part of the pharmaceutical sector’s solution to accessibility and digital healthcare,” it said. — Bernama


转载说明:本文转载自Sunbet。

上一篇:U8hash官网(www.eth108.vip):Artroniq ventures into the money lending business

下一篇:Telegram美国群(www.tel8.vip):Unitrade proposes 30% dividend payout for FY22

网友评论